Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

C. Confavreux, P. O'Connor, G. Comi, M.S. Freedman, A.E. Miller, T.P. Olsson, J.S. Wolinsky, T. Bagulho, J.L. Delhay, D. Dukovic, F. Barkhof, P. Truffinet, L. Kappos

Research output: Contribution to journalArticleAcademicpeer-review

442 Citations (Scopus)
Original languageEnglish
Pages (from-to)247-256
JournalLancet neurology
Issue number3
Publication statusPublished - 2014

Cite this